Publications by authors named "U Shah"
Background: The medial temporal lobe's (MTL) early involvement in tau pathology makes it a key focus in the development of preclinical Alzheimer's disease (AD) biomarkers. ROI analyses in prior studies reported significant MTL structural differences in cognitively normal individuals with and without β-amyloid (A+/-CN). Pointwise analysis, offering spatial information of early neurodegeneration, has potential to pinpoint "signature regions" of pathological change, but has been underexplored in the MTL.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is defined by the presence of ß-amyloid (Aß) plaques and tau-based neurofibrillary tangles (NFTs). Understanding the temporal relationship of NFTs with atrophy in early AD regions, specifically the medial temporal lobe (MTL), is critical for monitoring disease progression. Accumulation of NFTs has been suggested to precede atrophy because cross-sectional measures of atrophy are more weakly associated with baseline tracer uptake than prospective longitudinal ones.
View Article and Find Full Text PDFBackground: The medial temporal lobe's (MTL) early involvement in tau pathology makes it a key focus in the development of preclinical Alzheimer's disease (AD) biomarkers. ROI analyses in prior studies reported significant MTL structural differences in cognitively normal individuals with and without ß-amyloid (A+/-CN). Pointwise analysis, offering spatial information of early neurodegeneration, has potential to pinpoint "signature regions" of pathological change, but has been underexplored in the MTL.
View Article and Find Full Text PDFArticle Synopsis
- Earth-abundant kesterite Cu2ZnSn(S,Se)4 (CZTSSe) solar cells face efficiency challenges due to deep-level defects, which result in short carrier diffusion lengths, band tailing, and significant open-circuit voltage deficits.
- A proposed solution involves a post-fabrication treatment where the CZTSSe film is dip-coated in dimethylformamide (DMF), a polar solvent that helps neutralize defects and improve film quality, leading to larger grain sizes.
- As a result of this treatment, carrier diffusion length increased from 93 nm to 142 nm, reducing the VOC deficit by up to 289 mV and boosting the solar cell efficiency to 11.4%, showcasing the promise of DMF
Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.
Methods: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 10 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).